(1S,2R)-2-amino-1-phenylpropan-1-ol

• ChemBase编号: 280
• 分子式: C9H13NO
• 平均质量: 151.20562
• 单一同位素质量: 151.09971404
• SMILES: O[C@H]([C@H](N)C)c1ccccc1
• Canonical SMILES: O[C@@H](c1ccccc1)[C@H](N)C
• InChI: InChI=1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m1/s1
• InChIKey: DLNKOYKMWOXYQA-VXNVDRBHSA-N

名称和登记号

名称

• IUPAC标准名: (1S,2R)-2-amino-1-phenylpropan-1-ol
• IUPAC传统名: phenylpropanolamine
• 商标名: Acutrim; Ami-Tex; Codimal; Conex; Contuss; Despec; Dexatrim; Dura-Vent; Entex; Gentab; Guaipax; Myminic; Naldecon; Nolex; Partuss; Phenoxine; Phenyldrine; Phenylfenesin; Propagest; Rhindecon; Rhymed; Snaplets; Triaminic; ULR; Vanex
• 别名: (1S,2R)-2-氨基-1-苯基-1-丙醇; D-(+)-去甲麻黄素; 苯丙醇胺; 赤型-α-(1-氨基乙基)苄醇; (1S,2R)-(+)-去甲麻黄素; D-(+)-去甲麻黄素; (1S,2R)-2-Amino-1-phenyl-1-propanol; erythro-α-(1-aminoethyl)benzyl alcohol; D-(+)-Norephedrine; Phenylpropanolamine; (1S,2R)-(+)-Norephedrine; (+-)-Phenylpropanolamine; (+/-)-Norephedrin; PPA; Phenylpropanolamine; D-(+)-Norephedrine

登记号

• CAS号: 37577-28-9; 14838-15-4
• MDL号: MFCD00064411
• Beilstein号: 2802896
• PubChem SID: 160963743; 24859081; 46508087; 24886491
• PubChem CID: 26934

理论计算性质

JChem

• Acid pKa: 13.896164
• 质子受体: 2
• 质子供体: 2
• LogD (pH = 5.5): -2.0889428
• LogD (pH = 7.4): -1.0537072
• Log P: 0.8852543
• 摩尔折射率: 44.9127 cm^3
• 极化性: 18.00672 Å^3
• 极化表面积: 46.25 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 0.57
• LOG S: -0.87
• 溶解度: 2.06e+01 g/l

分子性质

理化性质

• 溶解度: Freely soluble
• 熔点: 51-54 °C(lit.)
• 闪点: 113 °C; 235.4 °F
• 比旋光度: [α]20/D +40.0±1°, c = 7% in 1 M HCl; [α]20/D +40°, c = 7 in 1 M HCl
• 疏水性(logP): 1

安全信息

• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22-36/37/38
• 安全公开号: 26
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H302-H315-H319-H335
• GHS警示性声明: P261-P305 + P351 + P338
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• 保存温度: 2-8°C

产品相关信息

• 纯度: ≥98.0% (NT); 98%
• 级别: purum
• 线性分子式: C6H5CH(OH)CH(CH3)NH2
• Empirical Formula (Hill Notation): C9H13NO

详细说明

DrugBank - DB00397

• Drug Groups: approved; withdrawn
• Description: Phenylpropanolamine has been withdrawn in Canada. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug.
• Indication: For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.
• Pharmacology: Phenylpropanolamine (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Phenylpropanolamine is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing phenylpropanolamine, due to an increased risk of hemorrhagic stroke in women who used phenylpropanolamine.
• Toxicity: May induce ventricular extrasystoles and short paroxysms of ventricular tachycardia, a sensation of fullness in the head and tingling of the extremities; LD₅₀=1490mg/kg (orally in rat)
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic
• Absorption: Reduced bioavailability (about 38%) from gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver.
• Half Life: 2.1 to 3.4 hours.
• External Links: Wikipedia; Drugs.com

Sigma Aldrich - 317500

包装
10, 50 g in glass bottle